Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera ...

The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

Pfizer Inc said on Monday it has filed a second lawsuit against its controlling shareholder, Metsera, and Novo Nordisk in a ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.

Pfizer has filed a second lawsuit against Danish pharmaceutical giant Novo Nordisk, accusing the company of deliberately stalling its $9 billion bid for biotech firm Metsera to hinder competition in ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.